Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children.

Klinger B, Silbergeld A, Deghenghi R, Frenkel J, Laron Z

European journal of endocrinology1 Jun 1996Cited by 23 (Europe PMC)

PMID8766941DOI10.1530/eje.0.1340716PepBankPUB-08766941

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialActivity measurement
In prepubertal short children, the mean peak hGH rise to an intranasal hexarelin bolus fell after 7 days of hexarelin treatment (p < 0.002).
In plain wordsIn short children, the growth hormone rise to hexarelin was smaller after 7 days of hexarelin treatment than before.
Peptide
Hexarelin
Outcome
DecreasePeak hGH response to intranasal hexarelin bolus after 7 days of treatment
Study
n = 7
Comparator
Before treatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
60 micrograms/kg t.i.d. · intranasal · 7 daysAs given in this study (human).
Measurements
peak hGH rise
70.6 mU/l
before treatment
peak hGH rise
34.1 mU/l
after 7 days
Source sentences
Summary
The mean ( +/- SD) peak rise of hGH to the intranasal bolus before treatment was 70.6 +/- 28.2 mU/l. After 7 days of hexarelin treatment, mean peak values dropped to 34.1 +/- 15.7 mU/l (p < 0.002) and thereafter remained constant for 6 months of treatment at 37.5 +/- 10.3 mU/l (p < 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
Hexarelin (60 micrograms/kg t.i.d.) was administered to seven prepubertal constitutionally short children (mean age +/- SD = 7.6 +/- 2.4 years).
Summary · context
Serum human growth hormone (hGH) response to an intranasal (20 micrograms/kg) and i.v. (1 mircogram/kg) bolus of hexarelin before, during and after 6-10 months of treatment was measured.
Report a problemFND-0876694101
02HumanNon-randomized trialActivity measurement
In prepubertal short children, the mean peak hGH rise to an intranasal hexarelin bolus remained lower than before treatment over 6 months of treatment (p < 0.03).
In plain wordsIn short children, the growth hormone rise to hexarelin stayed smaller than before treatment over 6 months of treatment.
Peptide
Hexarelin
Outcome
DecreasePeak hGH response to intranasal hexarelin bolus after 6 months of treatment
Study
n = 7
Comparator
Before treatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
60 micrograms/kg t.i.d. · intranasal · 6 monthsAs given in this study (human).
Measurements
peak hGH rise
70.6 mU/l
before treatment
peak hGH rise
37.5 mU/l
6 months of treatment
Source sentences
Summary
The mean ( +/- SD) peak rise of hGH to the intranasal bolus before treatment was 70.6 +/- 28.2 mU/l. After 7 days of hexarelin treatment, mean peak values dropped to 34.1 +/- 15.7 mU/l (p < 0.002) and thereafter remained constant for 6 months of treatment at 37.5 +/- 10.3 mU/l (p < 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
Hexarelin (60 micrograms/kg t.i.d.) was administered to seven prepubertal constitutionally short children (mean age +/- SD = 7.6 +/- 2.4 years).
Summary · context
Serum human growth hormone (hGH) response to an intranasal (20 micrograms/kg) and i.v. (1 mircogram/kg) bolus of hexarelin before, during and after 6-10 months of treatment was measured.
Report a problemFND-0876694102
03HumanNon-randomized trialActivity measurement
In prepubertal short children, the peak hGH response to an i.v. hexarelin bolus was lower at the end of treatment than before treatment (p < 0.05).
In plain wordsIn short children, the growth hormone rise to an injected hexarelin dose was smaller at the end of treatment than before.
Peptide
Hexarelin
Outcome
DecreasePeak hGH response to i.v. hexarelin bolus at end of treatment
Study
n = 7
Comparator
Before treatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
60 micrograms/kg t.i.d. · intranasal · 6-10 monthsAs given in this study (human).
Measurements
peak hGH response
84.8 mU/l
before treatment
peak hGH response
19.8 mU/l
end of treatment
Source sentences
Summary
The pretreatment peak to th i.v. hexarelin bolus was 84.8 +/- 52.5 mU/l, and at the end of the treatment period it was 19.8 +/- 10.9 mU/l (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Hexarelin (60 micrograms/kg t.i.d.) was administered to seven prepubertal constitutionally short children (mean age +/- SD = 7.6 +/- 2.4 years).
Summary · context
Serum human growth hormone (hGH) response to an intranasal (20 micrograms/kg) and i.v. (1 mircogram/kg) bolus of hexarelin before, during and after 6-10 months of treatment was measured.
Report a problemFND-0876694103
04HumanNon-randomized trialActivity measurement
In prepubertal short children, the mean hGH response rose to 42.1 mU/l three months after stopping hexarelin treatment (p < 0.005).
In plain wordsIn short children, the growth hormone response to hexarelin partly returned three months after treatment stopped.
Peptide
Hexarelin
Outcome
IncreasehGH response 3 months after stopping treatment
Study
n = 7
Comparator
End of treatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
60 micrograms/kg t.i.d. · intranasal · 6-10 monthsAs given in this study (human).
Measurements
hGH response
42.1 mU/l
3 months after stopping treatment
Source sentences
Summary
Three months after stopping treatment the mean ( +/- SD) hGH response rose to 42.1 +/- 4.7 mU/l (p < 0.005).
2 context sentences(design, population, supporting numbers)
Summary · context
Hexarelin (60 micrograms/kg t.i.d.) was administered to seven prepubertal constitutionally short children (mean age +/- SD = 7.6 +/- 2.4 years).
Summary · context
Serum human growth hormone (hGH) response to an intranasal (20 micrograms/kg) and i.v. (1 mircogram/kg) bolus of hexarelin before, during and after 6-10 months of treatment was measured.
Report a problemFND-0876694104
05HumanNon-randomized trialEfficacy outcome
In prepubertal short children, growth velocity increased from before treatment to 6-10 months of hexarelin treatment (p < 0.005).
In plain wordsIn short children, growth speed was higher after 6 to 10 months of hexarelin treatment than before, with no control group.
Peptide
Hexarelin
Outcome
IncreaseGrowth velocity
Study
n = 7
Comparator
Before treatment
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 micrograms/kg t.i.d. · intranasal · 6-10 monthsAs given in this study (human).
Measurements
growth velocity
5.3 cm/year
before treatment
growth velocity
7.4 cm/year
6-10 months of treatment
Source sentences
Summary
Growth velocity increased from 5.3 +/- 0.9 cm/year (before treatment) to 7.4 +/- 1.6 cm/year at 6-10 months of treatment (p < 0.005).
2 context sentences(design, population, supporting numbers)
Summary · context
Hexarelin (60 micrograms/kg t.i.d.) was administered to seven prepubertal constitutionally short children (mean age +/- SD = 7.6 +/- 2.4 years).
Summary · context
Serum human growth hormone (hGH) response to an intranasal (20 micrograms/kg) and i.v. (1 mircogram/kg) bolus of hexarelin before, during and after 6-10 months of treatment was measured.
Report a problemFND-0876694105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.